Now there's an in-depth and up-to-date reference you can turn to for help in managing two of the most common side effects of anti-cancer treatments: nausea and vomiting. Get the details on how the clinical application of 5-hydroxytryptamine receptor antagonists has transformed the management of these side effects -- and how it can dramatically improve the quality of life for your patients.
* Presents a detailed overview of the management of cancer treatment-induced emesis in various treatment settings * Focuses on the mechanisms and use of 5-HT3 receptor antagonists * Includes up-to-date results from major international trials * Keeps you completely informed with contributions from the points of view of the nurse and the patient
First published in 1997. Routledge is an imprint of Taylor & Francis, an informa company.
1. The evolution of antiemetic treatment
2. Methodology of trials for treating nausea and vomiting
3. Pharmacology of serotonin and its receptors
4. Clinical aspects and prognostic factors of nausea and vomiting after chemotherapy
5. Platinum-induced acute nausea and vomiting
6. Platinum-induced delayed emesis
7. Treatment of moderately emetogenic chemotherapy-induced nausea and vomiting
8. Treatment of radiotherapy-induced nausea and vomiting
9. Prevention of nausea and vomiting in repeat courses
10. Anticipatory nausea and vomiting: models, mechanisms and management
11. Are there differences between 5-HT3 receptor antagonists?
12. Quality of life
13. Patients' point of view
14. Emesis: A challenge for nurses
15. Nausea and vomiting in children
16. Side-effects of antiemetics
Mario A. Dicato M.D. Department of Haematology-Oncology, Centre Hospitalier de Luxembourg.
Rohkem infot Taylor & Francis e-raamatute kohta